{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:49:15Z","timestamp":1784260155619,"version":"3.55.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05730-1","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T05:21:18Z","timestamp":1749273678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tailoring prostate cancer external beam radiotherapy for patients with lower urinary tract symptoms"],"prefix":"10.1007","volume":"43","author":[{"given":"Jennifer","family":"Le Gu\u00e9velou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Peyrottes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne-Florence","family":"Jacquet-Kammerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Peyronnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Chargari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Anract","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"5730_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.eururo.2024.04.031","volume":"86","author":"M Creta","year":"2024","unstructured":"Creta M, Russo GI, Bhojani N et al (2024) Bladder outlet obstruction relief and symptom improvement following medical and surgical therapies for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review. Eur Urol 86:315\u2013326. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.031","journal-title":"Eur Urol"},{"key":"5730_CR2","doi-asserted-by":"publisher","unstructured":"Lebdai S, Doizi S, Kassab D et al (2024) Pre-therapeutical assessment of lower urinary tract symptoms in adult men: systematic review and clinical practice guidelines. Fr J Urol 102846. https:\/\/doi.org\/10.1016\/j.fjurol.2024.102846","DOI":"10.1016\/j.fjurol.2024.102846"},{"key":"5730_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/s0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474\u2013479. https:\/\/doi.org\/10.1016\/s0022-5347(17)49698-4","journal-title":"J Urol"},{"key":"5730_CR4","doi-asserted-by":"publisher","unstructured":"Isaacs JT (1994) Etiology of benign prostatic hyperplasia. Eur Urol 25 Suppl 16\u20139. https:\/\/doi.org\/10.1159\/000475324","DOI":"10.1159\/000475324"},{"key":"5730_CR5","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/ijc.29538","volume":"137","author":"KJL Bell","year":"2015","unstructured":"Bell KJL, Del Mar C, Wright G et al (2015) Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer 137:1749\u20131757. https:\/\/doi.org\/10.1002\/ijc.29538","journal-title":"Int J Cancer"},{"key":"5730_CR6","first-page":"805","volume":"19","author":"Z-Q Tao","year":"2015","unstructured":"Tao Z-Q, Shi A-M, Wang K-X, Zhang W-D (2015) Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci 19:805\u2013812","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"5730_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.ijrobp.2004.07.715","volume":"61","author":"STH Peeters","year":"2005","unstructured":"Peeters STH, Heemsbergen WD, van Putten WLJ et al (2005) Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61:1019\u20131034. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.07.715","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5730_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13014-017-0839-3","volume":"12","author":"M Jolnerovski","year":"2017","unstructured":"Jolnerovski M, Salleron J, Beckendorf V et al (2017) Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity. Radiat Oncol Lond Engl 12:99. https:\/\/doi.org\/10.1186\/s13014-017-0839-3","journal-title":"Radiat Oncol Lond Engl"},{"key":"5730_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.clon.2011.03.001","volume":"23","author":"GC Barnett","year":"2011","unstructured":"Barnett GC, De Meerleer G, Gulliford SL et al (2011) The impact of clinical factors on the development of late radiation toxicity: results from the medical research Council RT01 trial (ISRCTN47772397). Clin Oncol R Coll Radiol G B 23:613\u2013624. https:\/\/doi.org\/10.1016\/j.clon.2011.03.001","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"5730_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.radonc.2015.06.011","volume":"116","author":"N Yahya","year":"2015","unstructured":"Yahya N, Ebert MA, Bulsara M et al (2015) Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: an analysis of data from the RADAR prostate radiotherapy trial. Radiother Oncol J Eur Soc Ther Radiol Oncol 116:112\u2013118. https:\/\/doi.org\/10.1016\/j.radonc.2015.06.011","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"5730_CR11","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1016\/j.prro.2015.02.001","volume":"5","author":"ZA Seymour","year":"2015","unstructured":"Seymour ZA, Chang AJ, Zhang L et al (2015) Dose-volume analysis and the Temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol 5:e465\u2013e472. https:\/\/doi.org\/10.1016\/j.prro.2015.02.001","journal-title":"Pract Radiat Oncol"},{"key":"5730_CR12","doi-asserted-by":"publisher","unstructured":"Katz AJ, Kang J (2014) Quality of life and toxicity after SBRT for Organ-Confined prostate cancer, a 7-Year study. Front Oncol 4. https:\/\/doi.org\/10.3389\/fonc.2014.00301","DOI":"10.3389\/fonc.2014.00301"},{"key":"5730_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13014-014-0241-3","volume":"9","author":"E Janowski","year":"2014","unstructured":"Janowski E, Chen LN, Kim JS et al (2014) Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (\u2265\u200950 cm3). Radiat Oncol 9:241. https:\/\/doi.org\/10.1186\/s13014-014-0241-3","journal-title":"Radiat Oncol"},{"key":"5730_CR14","first-page":"340","volume":"15","author":"JE McNeal","year":"1978","unstructured":"McNeal JE (1978) Origin and evolution of benign prostatic enlargement. Invest Urol 15:340\u2013345","journal-title":"Invest Urol"},{"key":"5730_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0094-0143(21)00961-7","volume":"17","author":"J McNeal","year":"1990","unstructured":"McNeal J (1990) Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 17:477\u2013486","journal-title":"Urol Clin North Am"},{"key":"5730_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.diff.2013.02.006","volume":"85","author":"TM Nicholson","year":"2013","unstructured":"Nicholson TM, Sehgal PD, Drew SA et al (2013) Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment. Differ Res Biol Divers 85:140\u2013149. https:\/\/doi.org\/10.1016\/j.diff.2013.02.006","journal-title":"Differ Res Biol Divers"},{"key":"5730_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/j.1939-4640.1998.tb02036.x","volume":"19","author":"S Monti","year":"1998","unstructured":"Monti S, Di Silverio F, Toscano V et al (1998) Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH). J Androl 19:428\u2013433","journal-title":"J Androl"},{"key":"5730_CR18","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1097\/01.ju.0000133655.71782.14","volume":"172","author":"KL Lee","year":"2004","unstructured":"Lee KL, Peehl DM (2004) Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 172:1784\u20131791. https:\/\/doi.org\/10.1097\/01.ju.0000133655.71782.14","journal-title":"J Urol"},{"key":"5730_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jare.2023.04.006","volume":"57","author":"B-R Jin","year":"2023","unstructured":"Jin B-R, Kim H-J, Na J-H et al (2023) Targeting benign prostate hyperplasia treatments: AR\/TGF-\u03b2\/NOX4 Inhibition by Apocynin suppresses inflammation and proliferation. J Adv Res 57:135. https:\/\/doi.org\/10.1016\/j.jare.2023.04.006","journal-title":"J Adv Res"},{"key":"5730_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/09687688.2014.894211","volume":"31","author":"S Hu","year":"2014","unstructured":"Hu S, Yu W, Lv T-J et al (2014) Evidence of TGF-\u03b21 mediated epithelial-mesenchymal transition in immortalized benign prostatic hyperplasia cells. Mol Membr Biol 31:103\u2013110. https:\/\/doi.org\/10.3109\/09687688.2014.894211","journal-title":"Mol Membr Biol"},{"key":"5730_CR21","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/pros.23365","volume":"77","author":"T Pej\u010di\u0107","year":"2017","unstructured":"Pej\u010di\u0107 T, Tosti T, Te\u0161i\u0107 \u017d et al (2017) Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume. Prostate 77:1082\u20131092. https:\/\/doi.org\/10.1002\/pros.23365","journal-title":"Prostate"},{"key":"5730_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"J-P Copp\u00e9","year":"2010","unstructured":"Copp\u00e9 J-P, Desprez P-Y, Krtolica A, Campisi J (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5:99\u2013118. https:\/\/doi.org\/10.1146\/annurev-pathol-121808-102144","journal-title":"Annu Rev Pathol"},{"key":"5730_CR23","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.eururo.2006.12.011","volume":"51","author":"G Kramer","year":"2007","unstructured":"Kramer G, Mitteregger D, Marberger M (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51:1202\u20131216. https:\/\/doi.org\/10.1016\/j.eururo.2006.12.011","journal-title":"Eur Urol"},{"key":"5730_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/01.mou.0000193368.91823.1b","volume":"16","author":"G Kramer","year":"2006","unstructured":"Kramer G, Marberger M (2006) Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 16:25\u201329","journal-title":"Curr Opin Urol"},{"key":"5730_CR25","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.eururo.2007.11.026","volume":"54","author":"JC Nickel","year":"2008","unstructured":"Nickel JC, Roehrborn CG, O\u2019Leary MP et al (2008) The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 54:1379\u20131384. https:\/\/doi.org\/10.1016\/j.eururo.2007.11.026","journal-title":"Eur Urol"},{"key":"5730_CR26","doi-asserted-by":"crossref","unstructured":"Roehrborn CG, Kaplan SA, Noble WD et al (2005) The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. AUA Meeting; Abstract 1277.","DOI":"10.1016\/S0022-5347(18)35422-3"},{"key":"5730_CR27","first-page":"59","volume":"43","author":"ARAH Hamid","year":"2011","unstructured":"Hamid ARAH, Umbas R, Mochtar CA (2011) Recent role of inflammation in prostate diseases: chemoprevention development opportunity. Acta Med Indones 43:59\u201365","journal-title":"Acta Med Indones"},{"key":"5730_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000366210","volume":"94","author":"PL Minciullo","year":"2015","unstructured":"Minciullo PL, Inferrera A, Navarra M et al (2015) Oxidative stress in benign prostatic hyperplasia: a systematic review. Urol Int 94:249\u2013254. https:\/\/doi.org\/10.1159\/000366210","journal-title":"Urol Int"},{"key":"5730_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1464-410X.2008.07493.x","volume":"3","author":"P Geppetti","year":"2008","unstructured":"Geppetti P, Nassini R, Materazzi S, Benemei S (2008) The concept of neurogenic inflammation. BJU Int 101 Suppl 3:2\u20136. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.07493.x","journal-title":"BJU Int 101 Suppl"},{"key":"5730_CR30","doi-asserted-by":"publisher","unstructured":"McLaren ID, Jerde TJ, Bushman W (2011) Role of interleukins, IGF and stem cells in BPH. Differ Res Biol Divers 82. https:\/\/doi.org\/10.1016\/j.diff.2011.06.001","DOI":"10.1016\/j.diff.2011.06.001"},{"key":"5730_CR31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.juro.2015.07.102","volume":"195","author":"N Hinata","year":"2016","unstructured":"Hinata N, Miyake H, Murakami G et al (2016) Bladder neck muscle degeneration in patients with prostatic hyperplasia. J Urol 195:206\u2013212. https:\/\/doi.org\/10.1016\/j.juro.2015.07.102","journal-title":"J Urol"},{"key":"5730_CR32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0022-5347(01)61783-X","volume":"161","author":"E Inui","year":"1999","unstructured":"Inui E, Ochiai A, Naya Y et al (1999) Comparative morphometric study of bladder detrusor between patients with benign prostatic hyperplasia and controls. J Urol 161:827\u2013830","journal-title":"J Urol"},{"key":"5730_CR33","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/s0022-5347(17)61195-9","volume":"107","author":"JE McNeal","year":"1972","unstructured":"McNeal JE (1972) The prostate and prostatic urethra: a morphologic synthesis. J Urol 107:1008\u20131016. https:\/\/doi.org\/10.1016\/s0022-5347(17)61195-9","journal-title":"J Urol"},{"key":"5730_CR34","first-page":"1297","volume-title":"Campbell\u2019s urology","author":"CG Roehrborn","year":"2002","unstructured":"Roehrborn CG, McConnell JD (2002) Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED Jr and Wein A.J. (eds) Campbell\u2019s urology, 8th edn. WB Saunders Co., Philadelphia, PA, pp 1297\u20131336","edition":"8"},{"key":"5730_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.14670\/HH-29.57","volume":"29","author":"MA Babinski","year":"2014","unstructured":"Babinski MA, Manaia JHM, Cardoso GP et al (2014) Significant decrease of extracellular matrix in prostatic urethra of patients with benign prostatic hyperplasia. Histol Histopathol 29:57\u201363. https:\/\/doi.org\/10.14670\/HH-29.57","journal-title":"Histol Histopathol"},{"key":"5730_CR36","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.ijrobp.2019.06.490","volume":"105","author":"DH Brand","year":"2019","unstructured":"Brand DH, Tree A, Ostler P et al (2019) Patient reported acute toxicity in PACE-B, an international phase III randomised controlled trial comparing stereotactic body radiotherapy to conventionally fractionated or moderately hypofractionated radiotherapy (CFMHRT) for localised prostate Cancer. Int J Radiat Oncol Biol Phys 105:S55\u2013S56. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.06.490","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5730_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.radonc.2019.12.006","volume":"145","author":"V Murthy","year":"2020","unstructured":"Murthy V, Maitre P, Bhatia J et al (2020) Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial. Radiother Oncol 145:71\u201380. https:\/\/doi.org\/10.1016\/j.radonc.2019.12.006","journal-title":"Radiother Oncol"},{"key":"5730_CR38","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","volume":"75","author":"B Peyronnet","year":"2019","unstructured":"Peyronnet B, Mironska E, Chapple C et al (2019) A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol 75:988\u20131000. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.038","journal-title":"Eur Urol"},{"key":"5730_CR39","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.euo.2021.07.005","volume":"4","author":"JN Staffurth","year":"2021","unstructured":"Staffurth JN, Haviland JS, Wilkins A et al (2021) Impact of hypofractionated radiotherapy on Patient-reported outcomes in prostate cancer: results up to 5 year in the CHHiP trial (CRUK\/06\/016). Eur Urol Oncol 4:980\u2013992. https:\/\/doi.org\/10.1016\/j.euo.2021.07.005","journal-title":"Eur Urol Oncol"},{"key":"5730_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.prro.2023.11.008","volume":"14","author":"JC Hurwitz","year":"2024","unstructured":"Hurwitz JC, Haas J, Mendez C et al (2024) Stereotactic body radiation therapy for the curative treatment of prostate Cancer in ultralarge (\u2265\u2009100\u00a0cc) glands. Pract Radiat Oncol 14:241\u2013251. https:\/\/doi.org\/10.1016\/j.prro.2023.11.008","journal-title":"Pract Radiat Oncol"},{"key":"5730_CR41","doi-asserted-by":"publisher","first-page":"103661","DOI":"10.1016\/j.critrevonc.2022.103661","volume":"173","author":"A Lapierre","year":"2022","unstructured":"Lapierre A, Hennequin C, Beneux A et al (2022) Highly hypofractionated schedules for localized prostate cancer: recommendations of the GETUG radiation oncology group. Crit Rev Oncol Hematol 173:103661. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103661","journal-title":"Crit Rev Oncol Hematol"},{"key":"5730_CR42","doi-asserted-by":"publisher","unstructured":"Sinzabakira F, Brand V, Heemsbergen WD, Incrocci L (2023) Acute and late toxicity patterns of moderate hypo-fractionated radiotherapy for prostate cancer: A systematic review and meta-analysis. Clin Transl Radiat Oncol 40. https:\/\/doi.org\/10.1016\/j.ctro.2023.100612","DOI":"10.1016\/j.ctro.2023.100612"},{"key":"5730_CR43","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"391","author":"N van As","year":"2024","unstructured":"van As N, Griffin C, Tree A et al (2024) Phase 3 trial of stereotactic body radiotherapy in localized prostate Cancer. N Engl J Med 391:1413\u20131425. https:\/\/doi.org\/10.1056\/NEJMoa2403365","journal-title":"N Engl J Med"},{"key":"5730_CR44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1748-717X-8-58","volume":"8","author":"LN Chen","year":"2013","unstructured":"Chen LN, Suy S, Uhm S et al (2013) Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown university experience. Radiat Oncol 8:58. https:\/\/doi.org\/10.1186\/1748-717X-8-58","journal-title":"Radiat Oncol"},{"key":"5730_CR45","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ijrobp.2013.08.019","volume":"87","author":"CR King","year":"2013","unstructured":"King CR, Collins S, Fuller D et al (2013) Health-Related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a Multi-institutional consortium of prospective trials. Int J Radiat Oncol 87:939\u2013945. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.08.019","journal-title":"Int J Radiat Oncol"},{"key":"5730_CR46","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1200\/JCO.2013.53.8652","volume":"32","author":"JB Yu","year":"2014","unstructured":"Yu JB, Cramer LD, Herrin J et al (2014) Stereotactic body radiation therapy versus Intensity-Modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol 32:1195\u20131201. https:\/\/doi.org\/10.1200\/JCO.2013.53.8652","journal-title":"J Clin Oncol"},{"key":"5730_CR47","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41391-020-0249-8","volume":"24","author":"NG Nickols","year":"2021","unstructured":"Nickols NG, Ganapathy E, Nguyen C et al (2021) The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. Prostate Cancer Prostatic Dis 24:135\u2013139. https:\/\/doi.org\/10.1038\/s41391-020-0249-8","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"5730_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41391-022-00498-6","volume":"26","author":"N Kane","year":"2023","unstructured":"Kane N, Romero T, Diaz-Perez S et al (2023) Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT. Prostate Cancer Prostatic Dis 26:207\u2013209. https:\/\/doi.org\/10.1038\/s41391-022-00498-6","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"5730_CR49","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s00066-020-01637-5","volume":"196","author":"B Frey","year":"2020","unstructured":"Frey B, Mika J, Jelonek K et al (2020) Systemic modulation of stress and immune parameters in patients treated for prostate adenocarcinoma by intensity-modulated radiation therapy or stereotactic ablative body radiotherapy. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al 196:1018\u20131033. https:\/\/doi.org\/10.1007\/s00066-020-01637-5","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"key":"5730_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijrobp.2019.02.047","volume":"110","author":"CW Song","year":"2021","unstructured":"Song CW, Glatstein E, Marks LB et al (2021) Biological principles of stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS): indirect cell death. Int J Radiat Oncol Biol Phys 110:21\u201334. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.02.047","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5730_CR51","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1126\/science.1082504","volume":"300","author":"M Garcia-Barros","year":"2003","unstructured":"Garcia-Barros M, Paris F, Cordon-Cardo C et al (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155\u20131159. https:\/\/doi.org\/10.1126\/science.1082504","journal-title":"Science"},{"key":"5730_CR52","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijrobp.2015.05.016","volume":"93","author":"CW Song","year":"2015","unstructured":"Song CW, Lee Y-J, Griffin RJ et al (2015) Indirect tumor cell death after High-Dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int J Radiat Oncol Biol Phys 93:166\u2013172. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.05.016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5730_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.radonc.2018.12.022","volume":"133","author":"S Supiot","year":"2019","unstructured":"Supiot S, Rousseau C, Dore M et al (2019) Reoxygenation during radiotherapy in intermediate-risk prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 133:16\u201319. https:\/\/doi.org\/10.1016\/j.radonc.2018.12.022","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"5730_CR54","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/pros.23763","volume":"79","author":"N Haga","year":"2019","unstructured":"Haga N, Akaihata H, Hata J et al (2019) The association between local arteriosclerosis of the prostatic arteries and chronic inflammation in human benign prostatic enlargement. Prostate 79:574\u2013582. https:\/\/doi.org\/10.1002\/pros.23763","journal-title":"Prostate"},{"key":"5730_CR55","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","volume":"82","author":"CR King","year":"2012","unstructured":"King CR, Brooks JD, Gill H, Presti JC (2012) Long-Term outcomes from a prospective trial of stereotactic body radiotherapy for Low-Risk prostate Cancer. Int J Radiat Oncol 82:877\u2013882. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.11.054","journal-title":"Int J Radiat Oncol"},{"key":"5730_CR56","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","volume":"7","author":"C Greco","year":"2021","unstructured":"Greco C, Pares O, Pimentel N et al (2021) Safety and efficacy of virtual prostatectomy with Single-Dose radiotherapy in patients with Intermediate-Risk prostate cancer: results from the PROSINT phase 2 randomized clinical trial. JAMA Oncol 7:700\u2013708. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0039","journal-title":"JAMA Oncol"},{"key":"5730_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","volume":"112","author":"JE Leeman","year":"2022","unstructured":"Leeman JE, Chen Y-H, Catalano P et al (2022) Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: A combined analysis of 23 prospective clinical trials. Int J Radiat Oncol Biol Phys 112:75\u201382. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.06.037","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5730_CR58","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","volume":"167","author":"VH Groen","year":"2022","unstructured":"Groen VH, van Schie M, Zuithoff NPA et al (2022) Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiother Oncol J Eur Soc Ther Radiol Oncol 167:127\u2013132. https:\/\/doi.org\/10.1016\/j.radonc.2021.12.027","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"5730_CR59","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1007\/s00345-023-04579-6","volume":"41","author":"J Le Guevelou","year":"2023","unstructured":"Le Guevelou J, Bosetti DG, Castronovo F et al (2023) State of the Art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature. World J Urol 41:3287\u20133299. https:\/\/doi.org\/10.1007\/s00345-023-04579-6","journal-title":"World J Urol"},{"issue":"23","key":"5730_CR60","doi-asserted-by":"publisher","first-page":"00301","DOI":"10.1016\/j.ijrobp.2023.03.057","volume":"0360\u20133016","author":"T Zilli","year":"2023","unstructured":"Zilli T, Jorcano S, Bral S et al (2023) Every-Other-Day versus Once-a-Week Urethra-Sparing prostate stereotactic body radiation therapy: 5-Year results of a randomized phase 2 trial. Int J Radiat Oncol Biol Phys S 0360\u20133016(23):00301\u201300302. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.03.057","journal-title":"Int J Radiat Oncol Biol Phys S"},{"key":"5730_CR61","doi-asserted-by":"publisher","first-page":"863655","DOI":"10.3389\/fonc.2022.863655","volume":"12","author":"C Greco","year":"2022","unstructured":"Greco C, Pares O, Pimentel N et al (2022) Urethra sparing with target motion mitigation in Dose-Escalated extreme hypofractionated prostate Cancer radiotherapy: 7-Year results from a phase II study. Front Oncol 12:863655. https:\/\/doi.org\/10.3389\/fonc.2022.863655","journal-title":"Front Oncol"},{"issue":"24","key":"5730_CR62","doi-asserted-by":"publisher","first-page":"00145","DOI":"10.1016\/j.prro.2024.05.009","volume":"S1879\u20138500","author":"J Le Gu\u00e9velou","year":"2024","unstructured":"Le Gu\u00e9velou J, Zilli T, Ferretti L et al (2024) Urinary organs-at-risk for prostate cancer external beam radiotherapy: contouring guidelines on behalf of the Francophone group of urological radiation therapy (GFRU). Pract Radiat Oncol S1879\u20138500(24):00145\u201300140. https:\/\/doi.org\/10.1016\/j.prro.2024.05.009","journal-title":"Pract Radiat Oncol"},{"key":"5730_CR63","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5301\/tj.5000681","volume":"103","author":"T Rancati","year":"2017","unstructured":"Rancati T, Palorini F, Cozzarini C et al (2017) Understanding urinary toxicity after radiotherapy for prostate cancer: first steps forward. Tumori J 103:395\u2013404. https:\/\/doi.org\/10.5301\/tj.5000681","journal-title":"Tumori J"},{"key":"5730_CR64","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.radonc.2013.04.007","volume":"107","author":"D Kok","year":"2013","unstructured":"Kok D, Gill S, Bressel M et al (2013) Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol 107:140\u2013146. https:\/\/doi.org\/10.1016\/j.radonc.2013.04.007","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"5730_CR65","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ijrobp.2011.11.047","volume":"84","author":"MJ Zelefsky","year":"2012","unstructured":"Zelefsky MJ, Kollmeier M, Cox B et al (2012) Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 84:125\u2013129. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.11.047","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5730_CR66","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1748-717X-6-145","volume":"6","author":"S Gill","year":"2011","unstructured":"Gill S, Thomas J, Fox C et al (2011) Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol Lond Engl 6:145. https:\/\/doi.org\/10.1186\/1748-717X-6-145","journal-title":"Radiat Oncol Lond Engl"},{"issue":"24","key":"5730_CR67","doi-asserted-by":"publisher","first-page":"02688","DOI":"10.1016\/j.eururo.2024.10.026","volume":"S0302\u20132838","author":"AU Kishan","year":"2024","unstructured":"Kishan AU, Lamb JM, Wilhalme H et al (2024) Magnetic resonance imaging versus computed tomography guidance for stereotactic body radiotherapy in prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial. Eur Urol S0302\u20132838(24):02688\u201302685. https:\/\/doi.org\/10.1016\/j.eururo.2024.10.026","journal-title":"Eur Urol"},{"key":"5730_CR68","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.juro.2015.06.100","volume":"194","author":"ZS Zumsteg","year":"2015","unstructured":"Zumsteg ZS, Spratt DE, Romesser PB et al (2015) Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate Cancer. J Urol 194:1624\u20131630. https:\/\/doi.org\/10.1016\/j.juro.2015.06.100","journal-title":"J Urol"},{"key":"5730_CR69","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer LGW, Groen VH, Pos FJ et al (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 39:787\u2013796. https:\/\/doi.org\/10.1200\/JCO.20.02873","journal-title":"J Clin Oncol"},{"issue":"24","key":"5730_CR70","doi-asserted-by":"publisher","first-page":"02701","DOI":"10.1016\/j.eururo.2024.11.006","volume":"S0302\u20132838","author":"G Ploussard","year":"2024","unstructured":"Ploussard G, Coloby P, Chevallier T et al (2024) Whole-gland or subtotal High-intensity focused ultrasound versus radical prostatectomy: the prospective, noninferiority, nonrandomized HIFI trial. Eur Urol S0302\u20132838(24):02701\u201302705. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.006","journal-title":"Eur Urol"},{"key":"5730_CR71","doi-asserted-by":"publisher","first-page":"e477","DOI":"10.1016\/j.prro.2020.12.005","volume":"11","author":"M-H Ta","year":"2021","unstructured":"Ta M-H, Nunes-Silva I, Barret E et al (2021) Focal brachytherapy for localized prostate cancer: midterm outcomes. Pract Radiat Oncol 11:e477\u2013e485. https:\/\/doi.org\/10.1016\/j.prro.2020.12.005","journal-title":"Pract Radiat Oncol"},{"key":"5730_CR72","doi-asserted-by":"publisher","first-page":"20150658","DOI":"10.1259\/bjr.20150658","volume":"88","author":"AU Kishan","year":"2015","unstructured":"Kishan AU, Park SJ, King CR et al (2015) Dosimetric benefits of Hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy. Br J Radiol 88:20150658. https:\/\/doi.org\/10.1259\/bjr.20150658","journal-title":"Br J Radiol"},{"key":"5730_CR73","doi-asserted-by":"publisher","first-page":"1143716","DOI":"10.3389\/fonc.2023.1143716","volume":"13","author":"PV Nguyen","year":"2023","unstructured":"Nguyen PV, Donneaux B, Louis C et al (2023) Stereotactic focal radiotherapy as an alternative treatment for low-risk prostate cancer: results of a single-arm monocenter Phase-II trial. Front Oncol 13:1143716. https:\/\/doi.org\/10.3389\/fonc.2023.1143716","journal-title":"Front Oncol"},{"key":"5730_CR74","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00066-021-01832-y","volume":"197","author":"P Nguyen","year":"2021","unstructured":"Nguyen P, Harz\u00e9e L, Retif P et al (2021) Prospective validation of stringent dose constraints for prostatic stereotactic radiation monotherapy: results of a single-arm phase II toxicity-oriented trial. Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al 197:1001\u20131009. https:\/\/doi.org\/10.1007\/s00066-021-01832-y","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"key":"5730_CR75","doi-asserted-by":"publisher","unstructured":"De Cock L, Draulans C, Pos FJ et al (2023) From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. Radiother Oncol J Eur Soc Ther Radiol Oncol 109713. https:\/\/doi.org\/10.1016\/j.radonc.2023.109713","DOI":"10.1016\/j.radonc.2023.109713"},{"key":"5730_CR76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1200\/jco.2015.33.7_suppl.6","volume":"33","author":"HC Quon","year":"2015","unstructured":"Quon HC, Ong A, Cheung P et al (2015) PATRIOT trial: randomized phase II study of prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time. J Clin Oncol 33:6\u20136. https:\/\/doi.org\/10.1200\/jco.2015.33.7_suppl.6","journal-title":"J Clin Oncol"},{"key":"5730_CR77","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.radonc.2020.04.039","volume":"149","author":"Y Alayed","year":"2020","unstructured":"Alayed Y, Quon H, Ong A et al (2020) Accelerating prostate stereotactic ablative body radiotherapy: efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT). Radiother Oncol J Eur Soc Ther Radiol Oncol 149:8\u201313. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.039","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"5730_CR78","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.ijrobp.2015.02.046","volume":"92","author":"G Bauman","year":"2015","unstructured":"Bauman G, Ferguson M, Lock M et al (2015) A phase 1\/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for High-Risk prostate Cancer. Int J Radiat Oncol 92:856\u2013862. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.02.046","journal-title":"Int J Radiat Oncol"},{"key":"5730_CR79","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","volume":"102","author":"HB Musunuru","year":"2018","unstructured":"Musunuru HB, D\u2019Alimonte L, Davidson M et al (2018) Phase 1\u20132 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with High-Risk prostate Cancer (SATURN): early toxicity and quality of life. Int J Radiat Oncol 102:1438\u20131447. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.07.2005","journal-title":"Int J Radiat Oncol"},{"key":"5730_CR80","doi-asserted-by":"publisher","unstructured":"Houlihan OA, Redmond K, Fairmichael C et al (2023) A randomized feasibility trial of stereotactic prostate radiation therapy with or without elective nodal irradiation in High-Risk localized prostate Cancer (SPORT trial). Int J Radiat Oncol S 0360301623002171. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.02.054","DOI":"10.1016\/j.ijrobp.2023.02.054"},{"key":"5730_CR81","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.radonc.2021.05.024","volume":"161","author":"HB Musunuru","year":"2021","unstructured":"Musunuru HB, Cheung P, Vesprini D et al (2021) Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): efficacy, toxicity and quality of life. Radiother Oncol J Eur Soc Ther Radiol Oncol 161:40\u201346. https:\/\/doi.org\/10.1016\/j.radonc.2021.05.024","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"5730_CR82","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.clon.2018.03.004","volume":"30","author":"V Murthy","year":"2018","unstructured":"Murthy V, Gupta M, Mulye G et al (2018) Early results of extreme hypofractionation using stereotactic body radiation therapy for High-risk, very High-risk and Node-positive prostate Cancer. Clin Oncol 30:442\u2013447. https:\/\/doi.org\/10.1016\/j.clon.2018.03.004","journal-title":"Clin Oncol"},{"key":"5730_CR83","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ijrobp.2021.10.137","volume":"113","author":"R Hannan","year":"2022","unstructured":"Hannan R, Salamekh S, Desai NB et al (2022) SABR for High-Risk prostate cancer: A prospective multilevel MRI-Based dose escalation trial. Int J Radiat Oncol 113:290\u2013301. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.10.137","journal-title":"Int J Radiat Oncol"},{"key":"5730_CR84","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.3390\/cancers14143484","volume":"14","author":"DMC Poon","year":"2022","unstructured":"Poon DMC, Yuan J, Yang B et al (2022) A prospective study of stereotactic body radiotherapy (SBRT) with concomitant Whole-Pelvic radiotherapy (WPRT) for High-Risk localized prostate Cancer patients using 1.5 Tesla magnetic resonance guidance: the preliminary clinical outcome. Cancers 14:3484. https:\/\/doi.org\/10.3390\/cancers14143484","journal-title":"Cancers"},{"key":"5730_CR85","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/01.coc.0000225412.24750.4c","volume":"29","author":"ED Crawford","year":"2006","unstructured":"Crawford ED, Kavanagh BD (2006) The role of alpha-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy. Am J Clin Oncol 29:517\u2013523. https:\/\/doi.org\/10.1097\/01.coc.0000225412.24750.4c","journal-title":"Am J Clin Oncol"},{"key":"5730_CR86","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/00000478-198209000-00006","volume":"6","author":"DG Bostwick","year":"1982","unstructured":"Bostwick DG, Egbert BM, Fajardo LF (1982) Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 6:541\u2013551. https:\/\/doi.org\/10.1097\/00000478-198209000-00006","journal-title":"Am J Surg Pathol"},{"key":"5730_CR87","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/s0360-3016(99)00232-1","volume":"45","author":"MJ Zelefsky","year":"1999","unstructured":"Zelefsky MJ, Ginor RX, Fuks Z, Leibel SA (1999) Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 45:567\u2013570. https:\/\/doi.org\/10.1016\/s0360-3016(99)00232-1","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5730_CR88","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1464-410X.2005.05346.x","volume":"95","author":"GS Merrick","year":"2005","unstructured":"Merrick GS, Butler WM, Wallner KE et al (2005) Brachytherapy-related dysuria. BJU Int 95:597\u2013602. https:\/\/doi.org\/10.1111\/j.1464-410X.2005.05346.x","journal-title":"BJU Int"},{"key":"5730_CR89","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/14656566.2019.1589452","volume":"20","author":"FZ M\u00f3nica","year":"2019","unstructured":"M\u00f3nica FZ, De Nucci G (2019) Tadalafil for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother 20:929\u2013937. https:\/\/doi.org\/10.1080\/14656566.2019.1589452","journal-title":"Expert Opin Pharmacother"},{"key":"5730_CR90","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/pros.22686","volume":"73","author":"L Vignozzi","year":"2013","unstructured":"Vignozzi L, Gacci M, Cellai I et al (2013) PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 73:1391\u20131402. https:\/\/doi.org\/10.1002\/pros.22686","journal-title":"Prostate"},{"key":"5730_CR91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1743-6109.2009.01511.x","volume":"7","author":"B Fibbi","year":"2010","unstructured":"Fibbi B, Morelli A, Vignozzi L et al (2010) Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 7:59\u201369. https:\/\/doi.org\/10.1111\/j.1743-6109.2009.01511.x","journal-title":"J Sex Med"},{"key":"5730_CR92","doi-asserted-by":"publisher","first-page":"e0242006","DOI":"10.1371\/journal.pone.0242006","volume":"15","author":"HY Kim","year":"2020","unstructured":"Kim HY, Lee DS (2020) A role for phosphodiesterase type 5 inhibitors in remodelling the urinary bladder after radiation exposure. PLoS ONE 15:e0242006. https:\/\/doi.org\/10.1371\/journal.pone.0242006","journal-title":"PLoS ONE"},{"key":"5730_CR93","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.3390\/ijms24054911","volume":"24","author":"Z Wang","year":"2023","unstructured":"Wang Z, Yang S, Li Y et al (2023) Simvastatin improves benign prostatic hyperplasia: role of Peroxisome-Proliferator-Activated Receptor-\u03b3 and classic WNT\/\u03b2-Catenin pathway. Int J Mol Sci 24:4911. https:\/\/doi.org\/10.3390\/ijms24054911","journal-title":"Int J Mol Sci"},{"key":"5730_CR94","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00345-015-1550-3","volume":"33","author":"X Zhang","year":"2015","unstructured":"Zhang X, Zeng X, Dong L et al (2015) The effects of Statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome. World J Urol 33:2071\u20132077. https:\/\/doi.org\/10.1007\/s00345-015-1550-3","journal-title":"World J Urol"},{"key":"5730_CR95","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1152\/physrev.00036.2005","volume":"86","author":"M Paul","year":"2006","unstructured":"Paul M, Poyan Mehr A, Kreutz R (2006) Physiology of local renin-angiotensin systems. Physiol Rev 86:747\u2013803. https:\/\/doi.org\/10.1152\/physrev.00036.2005","journal-title":"Physiol Rev"},{"key":"5730_CR96","doi-asserted-by":"publisher","first-page":"159","DOI":"10.7326\/0003-4819-152-3-201002020-00007","volume":"152","author":"J Rosenbloom","year":"2010","unstructured":"Rosenbloom J, Castro SV, Jimenez SA (2010) Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 152:159\u2013166. https:\/\/doi.org\/10.7326\/0003-4819-152-3-201002020-00007","journal-title":"Ann Intern Med"},{"key":"5730_CR97","doi-asserted-by":"publisher","first-page":"8261","DOI":"10.3390\/ijms25158261","volume":"25","author":"PF Boothe","year":"2024","unstructured":"Boothe PF, Kumar VP, Kong Y et al (2024) Radiation induced skin fibrosis (RISF): opportunity for angiotensin II-Dependent intervention. Int J Mol Sci 25:8261. https:\/\/doi.org\/10.3390\/ijms25158261","journal-title":"Int J Mol Sci"},{"key":"5730_CR98","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.radonc.2022.01.014","volume":"168","author":"SL Kerns","year":"2022","unstructured":"Kerns SL, Morlang AA, Lee SM et al (2022) Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate Cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 168:75. https:\/\/doi.org\/10.1016\/j.radonc.2022.01.014","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"5730_CR99","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ajpath.2023.09.010","volume":"194","author":"L Dos Santos","year":"2024","unstructured":"Dos Santos L, Carbone F, Pacreau E et al (2024) Cell plasticity in a mouse model of benign prostate hyperplasia drives amplification of Androgen-Independent epithelial cell populations sensitive to antioxidant therapy. Am J Pathol 194:30\u201351. https:\/\/doi.org\/10.1016\/j.ajpath.2023.09.010","journal-title":"Am J Pathol"},{"key":"5730_CR100","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s00345-022-04124-x","volume":"40","author":"RV David","year":"2022","unstructured":"David RV, Kahokehr AA, Lee J et al (2022) Incidence of genitourinary complications following radiation therapy for localised prostate cancer. World J Urol 40:2411\u20132422. https:\/\/doi.org\/10.1007\/s00345-022-04124-x","journal-title":"World J Urol"},{"key":"5730_CR101","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/s0022-5347(17)57011-1","volume":"121","author":"WA Jones","year":"1979","unstructured":"Jones WA, Miller EV, Sullivan LD, Chapman WH (1979) Severe prostatic calcification after radiation therapy for cancer. J Urol 121:828\u2013830. https:\/\/doi.org\/10.1016\/s0022-5347(17)57011-1","journal-title":"J Urol"},{"key":"5730_CR102","doi-asserted-by":"publisher","first-page":"e392","DOI":"10.1016\/j.clon.2022.05.021","volume":"34","author":"C Huck","year":"2022","unstructured":"Huck C, Achard V, Zilli T (2022) Surgical treatments of benign prostatic hyperplasia and prostate Cancer stereotactic radiotherapy: impact on Long-Term genitourinary toxicity. Clin Oncol R Coll Radiol G B 34:e392\u2013e399. https:\/\/doi.org\/10.1016\/j.clon.2022.05.021","journal-title":"Clin Oncol R Coll Radiol G B"},{"issue":"24","key":"5730_CR103","doi-asserted-by":"publisher","first-page":"02254","DOI":"10.1016\/j.eururo.2024.03.027","volume":"S0302\u20132838","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol S0302\u20132838(24):02254\u201302251. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","journal-title":"Eur Urol"},{"key":"5730_CR104","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/s0090-4295(97)00164-7","volume":"49","author":"VE Reuter","year":"1997","unstructured":"Reuter VE (1997) Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49:16\u201322. https:\/\/doi.org\/10.1016\/s0090-4295(97)00164-7","journal-title":"Urology"},{"key":"5730_CR105","doi-asserted-by":"publisher","first-page":"371","DOI":"10.5114\/jcb.2016.63377","volume":"8","author":"KR Jethwa","year":"2016","unstructured":"Jethwa KR, Furutani KM, Mynderse LA et al (2016) Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression. J Contemp Brachytherapy 8:371\u2013378. https:\/\/doi.org\/10.5114\/jcb.2016.63377","journal-title":"J Contemp Brachytherapy"},{"key":"5730_CR106","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.urolonc.2009.03.024","volume":"29","author":"JF Langenhuijsen","year":"2011","unstructured":"Langenhuijsen JF, van Lin EN, Hoffmann AL et al (2011) Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. Urol Oncol 29:52\u201357. https:\/\/doi.org\/10.1016\/j.urolonc.2009.03.024","journal-title":"Urol Oncol"},{"key":"5730_CR107","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","volume":"64","author":"M Oelke","year":"2013","unstructured":"Oelke M, Bachmann A, Descazeaud A et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64:118\u2013140. https:\/\/doi.org\/10.1016\/j.eururo.2013.03.004","journal-title":"Eur Urol"},{"key":"5730_CR108","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.radonc.2009.03.013","volume":"92","author":"V Fonteyne","year":"2009","unstructured":"Fonteyne V, Villeirs G, Lumen N, De Meerleer G (2009) Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 92:42\u201347. https:\/\/doi.org\/10.1016\/j.radonc.2009.03.013","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"5730_CR109","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.clon.2017.03.006","volume":"29","author":"K Byrne","year":"2017","unstructured":"Byrne K, Hruby G, Kneebone A et al (2017) Late genitourinary toxicity outcomes in 300 prostate Cancer patients treated with Dose-escalated Image-guided Intensity-modulated radiotherapy. Clin Oncol R Coll Radiol G B 29:617\u2013625. https:\/\/doi.org\/10.1016\/j.clon.2017.03.006","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"5730_CR110","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijrobp.2009.07.1680","volume":"78","author":"WD Heemsbergen","year":"2010","unstructured":"Heemsbergen WD, Al-Mamgani A, Witte MG et al (2010) Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs. 78 Gy): relationships with local dose, acute effects, and baseline characteristics. Int J Radiat Oncol Biol Phys 78:19\u201325. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.07.1680","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5730_CR111","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.radonc.2014.04.005","volume":"112","author":"S De Langhe","year":"2014","unstructured":"De Langhe S, De Meerleer G, De Ruyck K et al (2014) Integrated models for the prediction of late genitourinary complaints after high-dose intensity modulated radiotherapy for prostate cancer: making informed decisions. Radiother Oncol J Eur Soc Ther Radiol Oncol 112:95\u201399. https:\/\/doi.org\/10.1016\/j.radonc.2014.04.005","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"5730_CR112","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3389\/fonc.2020.00555","volume":"10","author":"A Pepin","year":"2020","unstructured":"Pepin A, Aghdam N, Shah S et al (2020) Urinary morbidity in men treated with stereotactic body radiation therapy (SBRT) for localized prostate Cancer following transurethral resection of the prostate (TURP). Front Oncol 10:555. https:\/\/doi.org\/10.3389\/fonc.2020.00555","journal-title":"Front Oncol"},{"key":"5730_CR113","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.prro.2019.04.003","volume":"9","author":"V Murthy","year":"2019","unstructured":"Murthy V, Sinha S, Kannan S et al (2019) Safety of prostate stereotactic body radiation therapy after transurethral resection of prostate (TURP): A propensity score matched pair analysis. Pract Radiat Oncol 9:347\u2013353. https:\/\/doi.org\/10.1016\/j.prro.2019.04.003","journal-title":"Pract Radiat Oncol"},{"key":"5730_CR114","doi-asserted-by":"publisher","first-page":"100779","DOI":"10.1016\/j.ctro.2024.100779","volume":"46","author":"M Galienne","year":"2024","unstructured":"Galienne M, Risbourg S, Lacornerie T et al (2024) Extreme hypofractionated stereotactic radiotherapy for localized prostate cancer: efficacy and late urinary toxicity according to transurethral resection of the prostate history. Clin Transl Radiat Oncol 46:100779. https:\/\/doi.org\/10.1016\/j.ctro.2024.100779","journal-title":"Clin Transl Radiat Oncol"},{"key":"5730_CR115","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13014-015-0351-6","volume":"10","author":"MK Gurka","year":"2015","unstructured":"Gurka MK, Chen LN, Bhagat A et al (2015) Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol Lond Engl 10:44. https:\/\/doi.org\/10.1186\/s13014-015-0351-6","journal-title":"Radiat Oncol Lond Engl"},{"key":"5730_CR116","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.ijrobp.2018.07.191","volume":"102","author":"K Wang","year":"2018","unstructured":"Wang K, Chen RC, Kane BL et al (2018) Patient and dosimetric predictors of genitourinary and bowel quality of life after prostate SBRT: secondary analysis of a Multi-institutional trial. Int J Radiat Oncol Biol Phys 102:1430\u20131437. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.07.191","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5730_CR117","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.euf.2023.08.013","volume":"10","author":"M Rieken","year":"2024","unstructured":"Rieken M, de Nunzio C, Cornu J-N et al (2024) Medical treatment incidence and persistence after surgical relief of lower urinary tract symptoms suggestive of benign prostatic obstruction: A critical analysis of the literature. Eur Urol Focus 10:421\u2013431. https:\/\/doi.org\/10.1016\/j.euf.2023.08.013","journal-title":"Eur Urol Focus"},{"key":"5730_CR118","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ijrobp.2024.06.003","volume":"120","author":"M Singh","year":"2024","unstructured":"Singh M, Maitre P, Krishnan A et al (2024) Late urinary toxicity after extreme or moderate hypofractionated prostate radiation therapy in patients with prior transurethral resection of prostate. Int J Radiat Oncol Biol Phys 120:1011\u20131020. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.06.003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5730_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.07.2142","author":"R Ratnakumaran","year":"2024","unstructured":"Ratnakumaran R, Zilli T (2024) Toxicity after prostate radiation therapy: addressing the transurethral resection of the prostate (TURP) challenge. Int J Radiat Oncol Biol Phys S. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.07.2142. 0360-3016(24)02956\u20130","journal-title":"Int J Radiat Oncol Biol Phys S"},{"key":"5730_CR120","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/JU.0000000000002184","volume":"206","author":"LB Lerner","year":"2021","unstructured":"Lerner LB, McVary KT, Barry MJ et al (2021) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART II-Surgical evaluation and treatment. J Urol 206:818\u2013826. https:\/\/doi.org\/10.1097\/JU.0000000000002184","journal-title":"J Urol"},{"key":"5730_CR121","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/JU.0000000000000280","volume":"202","author":"A Ibrahim","year":"2019","unstructured":"Ibrahim A, Alharbi M, Elhilali MM et al (2019) 18 years of holmium laser enucleation of the prostate: A single center experience. J Urol 202:795\u2013800. https:\/\/doi.org\/10.1097\/JU.0000000000000280","journal-title":"J Urol"},{"key":"5730_CR122","doi-asserted-by":"publisher","first-page":"e1672","DOI":"10.1002\/cnr2.1672","volume":"6","author":"BS Laughlin","year":"2023","unstructured":"Laughlin BS, Narang GL, Cheney SM et al (2023) Toxicity and outcomes after external beam irradiation for prostate cancer in patients with prior holmium laser enucleation of the prostate: early experience. Cancer Rep Hoboken NJ 6:e1672. https:\/\/doi.org\/10.1002\/cnr2.1672","journal-title":"Cancer Rep Hoboken NJ"},{"key":"5730_CR123","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s00345-024-05220-w","volume":"42","author":"E Wajswol","year":"2024","unstructured":"Wajswol E, Crompton DJ, Igel T et al (2024) Functional outcomes following external beam radiation therapy for patients with prior holmium laser enucleation of the prostate. World J Urol 42:504. https:\/\/doi.org\/10.1007\/s00345-024-05220-w","journal-title":"World J Urol"},{"key":"5730_CR124","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.euf.2023.02.005","volume":"10","author":"O Burkhardt","year":"2024","unstructured":"Burkhardt O, Abt D, Engeler D et al (2024) Prostatic artery embolization in patients with prostate cancer: A systematic review. Eur Urol Focus 10:387\u2013399. https:\/\/doi.org\/10.1016\/j.euf.2023.02.005","journal-title":"Eur Urol Focus"},{"key":"5730_CR125","doi-asserted-by":"publisher","first-page":"100694","DOI":"10.1016\/j.tvir.2020.100694","volume":"23","author":"I Kably","year":"2020","unstructured":"Kably I, Acharya V, Richardson AJ, Bhatia S (2020) Prostatic artery embolization in refractory hematuria of prostatic origin. Tech Vasc Interv Radiol 23:100694. https:\/\/doi.org\/10.1016\/j.tvir.2020.100694","journal-title":"Tech Vasc Interv Radiol"},{"key":"5730_CR126","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/jcm13010065","volume":"13","author":"L Moramarco","year":"2023","unstructured":"Moramarco L, Grande AM, Vertemati M, Aseni P (2023) Prostate artery embolization in the treatment of massive intractable bleeding from prostatic neoplasms: A case report and systematic review. J Clin Med 13:65. https:\/\/doi.org\/10.3390\/jcm13010065","journal-title":"J Clin Med"},{"key":"5730_CR127","doi-asserted-by":"publisher","first-page":"100619","DOI":"10.1016\/j.adro.2020.11.004","volume":"6","author":"J Peacock","year":"2021","unstructured":"Peacock J, Sikaria D, Maun-Garcia L et al (2021) A Proof-of-Concept study on the use of prostate artery embolization before definitive radiation therapy in prostate Cancer. Adv Radiat Oncol 6:100619. https:\/\/doi.org\/10.1016\/j.adro.2020.11.004","journal-title":"Adv Radiat Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05730-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05730-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05730-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:56:01Z","timestamp":1767966961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05730-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5730"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05730-1","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"361"}}